Drugs / BBD-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07595367 | Jun 2026 → Jun 2028 expected | immunoglobulin A vasculitis | Qifeng Zhang | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBD-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07595367 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Because BBD-1 multi-target immune enhancer targeting agent is a natural plant compound, no adverse reactions have been found so far.” NCT07595367 ↗ |